2026-09-18 Posted by TideChem view:59
Acetic acid is used across pharmaceutical chemistry as a pH modifier, buffer component, solvent, counterion source and process reagent. It can support peptide solubilization and purification, produce peptide acetate salts and provide an acidic aqueous phase during oligonucleotide lipid nanoparticle manufacturing.
Its role is sometimes misunderstood. Acetic acid is not the same as acetic anhydride, and glacial acetic acid is not automatically pharmaceutical grade. Selecting the correct material requires attention to concentration, water content, trace impurities, analytical performance and the quality controls appropriate to the intended process.
For regulated manufacturing, the selection should begin with a clear question: what function is the acetic acid expected to perform?
Acetic acid, also called ethanoic acid, is a weak organic acid with the formula CH₃COOH and a molecular weight of 60.05 g/mol. Its conjugate base is acetate.
Acetic acid has a pKa of approximately 4.76 in water. A mixture of acetic acid and an acetate salt, such as sodium acetate, provides useful buffering in the mildly acidic range.
Pure acetic acid can crystallize below approximately 16.7°C. The term “glacial” comes from the ice-like crystals that may form near this temperature.
Important distinctions include:
The USP-NF monograph defines glacial acetic acid as containing 99.5% to 100.5% acetic acid by weight. USP-NF monograph
“Glacial” describes a highly concentrated form of acetic acid. It does not establish whether the material is suitable for pharmaceutical manufacturing, chromatography or parenteral use.
Glacial acetic acid may be sold as:
Two products can both be labeled “glacial acetic acid” while having very different limits for water, trace metals, organic impurities, nonvolatile residue and documentation.
Dilute acetic acid can improve the solubility of some basic or amphiphilic peptides by changing their protonation state.
This approach is useful in analytical sample preparation and selected research workflows, but it is not universal. Acidic conditions may lower the solubility of another peptide or increase aggregation, hydrolysis or modification instability.
The minimum effective acid concentration should be determined experimentally.
Acetic acid may be added to reversed-phase HPLC mobile phases to lower pH and protonate basic groups within a peptide.
Compared with trifluoroacetic acid, acetic acid is:
It may provide better MS response than TFA but weaker chromatographic resolution for highly charged peptides. The choice should follow method-development data rather than a general preference.
Peptides purified under TFA-containing conditions are often obtained as TFA salts. Developers may exchange TFA for acetate to support formulation, biological testing or later manufacturing.
A peptide acetate preparation may contain:
Gross powder weight is therefore not the same as net peptide content.
Salt exchange must be confirmed analytically. Peptide mass spectrometry alone is generally insufficient because volatile counterions may be lost or poorly represented during ionization.
USP General Chapter <503> provides procedures for determining acetic acid in peptide preparations and recognizes acetate as a common peptide counterion. USP <503>
Relevant methods may include:
Both residual TFA and replacement acetate should be measured when the counterion composition is critical.
Acetic acid and sodium acetate can maintain a mildly acidic formulation pH. This may improve the solubility or chemical stability of selected peptides.
Formulation studies should evaluate:
A lower pH may reduce one degradation pathway while accelerating another. The buffer must be selected using stability-indicating data.
Acetic acid does not normally acetylate peptides efficiently under mild manufacturing conditions. N-terminal acetylation and resin capping more commonly use acetic anhydride or an activated acetate reagent.
This distinction matters because the reagents have different properties:
| Material | Typical role |
| Acetic acid | pH control, buffer preparation, solvent or counterion source |
| Acetic anhydride | Acetylation and capping of unreacted amino groups |
| Sodium acetate | Conjugate base used in acetate buffers |
| Activated acetate derivatives | Site-specific or controlled acetylation |
Acetic acid may be generated when acetic anhydride reacts with water. Rising acetic acid and water levels can therefore indicate loss of capping-reagent strength during storage or use.
Acetic acid may be used during the preparation, purification or pH adjustment of PEG derivatives. Its compatibility depends on the PEG functional group and conjugation chemistry.
Particular care is needed with:
For example, amine coupling with a PEG-NHS ester normally requires conditions in which the amine nucleophile is sufficiently unprotonated. Excess acetic acid can protonate the amine and reduce coupling efficiency. Water can simultaneously hydrolyze the activated ester.
A process may therefore use acidic conditions during an upstream purification step but require removal or neutralization of acetic acid before conjugation.
Developers should monitor:
Solid-phase phosphoramidite synthesis generally follows repeated detritylation, coupling, oxidation or sulfurization, and capping steps.
Acetic acid is not the main reagent in every step.
Dichloroacetic acid or trichloroacetic acid is more commonly used to remove the 5′-dimethoxytrityl protecting group. Acetic acid is usually too weak to replace these reagents directly under standard conditions.
Unreacted 5′-hydroxyl groups are commonly capped using acetic anhydride. Capping prevents failed sequences from participating in later coupling cycles and helps control deletion impurities.
Acetic acid forms as acetic anhydride reacts. Excess water or accumulated acetic acid can change capping performance.
A recent study also reported that acetic anhydride-based capping chemistry can contribute to guanine modification under some conditions, reinforcing the need to control capping reagents and synthetic-cycle parameters. Capping study
The standard phosphoramidite cycle and the distinction between DCA detritylation and acetic anhydride capping are described in this oligonucleotide manufacturing review.
Acetic acid or acetate buffer may be used during selected purification, desalting or formulation steps. Its effect on oligonucleotide charge and chromatographic behavior should be included in method development.
Residual acetate may need to be measured when it affects:
Acetate buffers are used in some RNA lipid nanoparticle processes.
During LNP formation, the nucleic acid is dissolved in a low-pH aqueous phase and rapidly mixed with ionizable lipids in ethanol. Acidic pH protonates the ionizable lipid, supporting interaction with negatively charged RNA.
Published processes have used acetate buffers in the approximate pH 4 to 6 range, often followed by dialysis or tangential-flow filtration into a different storage buffer. LNP formulation review
Acetic acid quality may influence:
The low-pH acetate phase is frequently a process medium rather than the final formulation buffer. These two uses should have separate specifications and process controls.
Technical material is intended for industrial synthesis, cleaning and general processing. It may lack sufficiently tight controls for pharmaceutical use.
It is generally unsuitable for clinical or commercial drug manufacturing unless extensively qualified for a specific non-product-contact application.
FCC material can provide defined food-use purity. It may be suitable for selected oral-product or early development applications after risk assessment.
Food-grade compliance does not automatically establish parenteral suitability, low endotoxin or pharmaceutical change control.
ACS reagent material is useful for general laboratory synthesis and analytical work. It may have good chemical-purity specifications but does not necessarily provide pharmaceutical supply-chain controls.
Chromatography grades may include controls for:
These grades are useful for mobile-phase preparation but are not automatically suitable as pharmaceutical excipients.
USP-NF, Ph. Eur. or another applicable pharmacopeial grade is usually the appropriate starting point for regulated formulation or manufacturing use.
Pharmacopeial compliance still may not cover every performance-related attribute required by a specific process.
For injectable products, the specification may need additional controls for:
“USP grade” does not automatically mean sterile or endotoxin-controlled.
| Attribute | Why it matters |
| Identity | Confirms acetic acid rather than another organic acid |
| Assay | Supports accurate concentration and buffer preparation |
| Water | Directly affects strength and reactive processes |
| Color and clarity | Helps detect contamination or degradation |
| Organic impurities | May affect synthesis and analytical background |
| Aldehydes | Can react with nucleophilic amino groups |
| Readily oxidizable substances | Indicates oxidation-sensitive impurities |
| Nonvolatile residue | Important for chromatography and final product quality |
| Trace metals | May catalyze oxidation or affect sensitive biomolecules |
| Chloride and sulfate | Indicate inorganic contamination |
| UV absorbance | Important for HPLC and UV-based assays |
| Endotoxin | Important for many parenteral applications |
| Bioburden | Supports microbiological control |
| Particles | Relevant to formulations and sensitive equipment |
The actual specification should follow a risk assessment. Not every attribute must be a routine release test if it is adequately controlled through supplier qualification or periodic verification.
Common testing methods include:
Analytical methods should be appropriate to the material’s purpose. A method used to release bulk glacial acetic acid may not be sensitive enough to quantify residual acetate in a purified peptide or oligonucleotide.
Concentrated acetic acid is corrosive, produces irritating vapor and is combustible. PubChem reports a flash point of approximately 40°C, while NIOSH lists an occupational exposure limit of 10 ppm as an eight-hour time-weighted average. PubChem, NIOSH
Facilities should follow the current supplier safety data sheet and site-specific risk assessment.
General controls include:
Dilution is exothermic. Adding water directly to a large quantity of concentrated acid can cause localized heating and splashing.
Because glacial acetic acid can crystallize below about 16.7°C, a cool warehouse may produce partial or complete solidification. If warming is required, follow a validated supplier-approved procedure. Assay uniformity should be restored before sampling or dispensing.
Common packaging may include glass, compatible polymers, fluoropolymer-lined closures or qualified bulk containers.
Compatibility depends on:
Material compatibility should not be assumed from a generic chemical-resistance chart when acetic acid is heated or stored for extended periods.
For pharmaceutical use, packaging should also protect against:
Smaller or single-use containers may be appropriate during development. Bulk manufacturing may require closed transfer systems and qualified intermediate containers.
A peptide is purified using TFA and converted to an acetate salt before formulation.
The development team measures residual TFA, acetate content, net peptide content, water and chromatographic purity. The process is not considered complete merely because acetic acid was added during lyophilization.
Key lesson: Salt exchange requires quantitative confirmation of both the removed and replacement counterions.
Acetic acid is used during upstream PEG-intermediate purification. Residual acid and water reduce the efficiency of the subsequent amine coupling step.
The process introduces a drying or buffer-exchange step and monitors residual acetic acid before conjugation.
Key lesson: Acetic acid can be compatible with one process stage and detrimental to the next.
An siRNA process uses sodium acetate buffer at pH 4.2 during mixing with ionizable lipids. Scale-up changes particle size and encapsulation efficiency.
The investigation evaluates acetate concentration, pH, mixing rate, ethanol ratio, RNA concentration and downstream buffer exchange.
Key lesson: Buffer quality matters, but it must be controlled together with mixing and formulation parameters.
For research use, a certificate of analysis may be sufficient. Clinical and commercial manufacturing normally require a broader supplier-quality package.
Review:
A switch between suppliers can change water, trace metals or organic impurity patterns even when both materials meet the same compendial monograph. Supplier comparability should focus on process-relevant attributes.
Tide Chem’s publicly documented capabilities include peptide raw materials, non-natural amino acids, PEG derivatives, phosphoramidites and CDMO support for peptide and small nucleic acid projects. The company also publishes technical guidance on the use of acetic acid in peptide solubilization, purification and counterion exchange. Acetic Acid for Peptides
These capabilities can support projects in which acetic acid use must be integrated with:
For acetic acid itself, buyers should request a current product-specific specification before describing Tide Chem as the supplier of a particular grade. The documentation should confirm assay, water, grade, impurity limits, packaging, manufacturing site and any endotoxin or particle controls.
Company-level CDMO and quality capabilities do not establish that every acetic acid grade or packaging format is currently available. Product-specific confirmation remains necessary. Tide Chem About Us, Quality Assurance
No. “Glacial” describes concentration. Technical, reagent, chromatography and pharmacopeial products can all be sold as glacial acetic acid.
Acetic acid alone is generally not an efficient acetylating reagent. Acetic anhydride or an activated acetate is more commonly used.
It may be used as a formulation component or provide acetate counterions in peptide acetate salts.
Usually not. Acetic acid is much weaker than TFA and does not normally provide equivalent resin cleavage or global deprotection.
Low-pH acetate buffer protonates ionizable lipids and supports interaction with negatively charged RNA during particle formation.
USP-NF compliance is a useful baseline but does not automatically confirm sterility, endotoxin control or suitability for a specific injectable formulation.
Ion chromatography, quantitative NMR or another validated counterion-specific method may be used, depending on the sample and required sensitivity.
ICH Q3C classifies acetic acid as a Class 3 solvent with relatively low toxic potential. Appropriate process controls and product specifications are still required. ICH Q3C
Acetic acid supports several stages of peptide and oligonucleotide manufacturing, but its function changes from process to process. It may serve as a solvent, pH modifier, acetate-buffer component, chromatographic additive or peptide counterion source.
It must also be distinguished from acetic anhydride, which is the more typical acetylating and capping reagent in peptide and oligonucleotide synthesis.
Grade selection should be based on intended use. Reagent and chromatography grades may be appropriate for laboratory or analytical work, while regulated manufacturing generally requires pharmacopeial compliance and additional application-specific controls.
The most important attributes are not always captured by assay alone. Water, organic impurities, trace metals, nonvolatile residue, microbial quality, packaging and supplier change control can directly affect process performance and final product quality.